Literature DB >> 20680008

Induction of liver fibrosis in a murine hepatoma model by thioacetamide is associated with enhanced tumor growth and suppressed antitumor immunity.

Ming-Chen Yang1, Chih-Peng Chang, Huan-Yao Lei.   

Abstract

Liver cirrhosis and hepatocellular carcinomas are two major causes of morbidity and mortality worldwide, and can synergistically interact to expedite the tumor progression. How fibrosis promotes the hepatoma growth remains completely unexplained. Using an in situ murine hepatoma model together with fibrosis induction by thioacetamide (TAA), the hepatoma growth and the immune factors in the fibrotic liver were analyzed. We found that TAA-fibrosis induction enhanced hepatoma cell growth in the liver and increased the mortality of hepatoma-bearing mice. The tumor-infiltrating CD4(+) or CD8(+) T cells are downregulated by fibrosis induction. The Foxp3(+) regulatory T cells (Treg) cells were induced. We conclude that fibrosis induction causes further immunosuppression, in which Treg cells exert a downregulation effect on the antitumor immunity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20680008     DOI: 10.1038/labinvest.2010.139

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  11 in total

Review 1.  Animal models of cholangiocarcinoma.

Authors:  Emilien Loeuillard; Samantha R Fischbach; Gregory J Gores; Sumera Rizvi
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-04-05       Impact factor: 5.187

2.  Hepatic stellate cells secretes type I collagen to trigger epithelial mesenchymal transition of hepatoma cells.

Authors:  Ming-Chen Yang; Chih-Jung Wang; Pao-Chi Liao; Chia-Jui Yen; Yan-Shen Shan
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

3.  Inflammation-Dependent IL18 Signaling Restricts Hepatocellular Carcinoma Growth by Enhancing the Accumulation and Activity of Tumor-Infiltrating Lymphocytes.

Authors:  Geoffrey J Markowitz; Pengyuan Yang; Jing Fu; Gregory A Michelotti; Rui Chen; Jianhua Sui; Bin Yang; Wen-Hao Qin; Zheng Zhang; Fu-Sheng Wang; Anna Mae Diehl; Qi-Jing Li; Hongyang Wang; Xiao-Fan Wang
Journal:  Cancer Res       Date:  2016-02-18       Impact factor: 12.701

4.  Inflammatory models drastically alter tumor growth and the immune microenvironment in hepatocellular carcinoma.

Authors:  Geoffrey J Markowitz; Gregory A Michelotti; Anna Mae Diehl; Xiao-Fan Wang
Journal:  Sci Bull (Beijing)       Date:  2015-04-01       Impact factor: 11.780

Review 5.  Liver carcinogenesis: rodent models of hepatocarcinoma and cholangiocarcinoma.

Authors:  Samuele De Minicis; Tatiana Kisseleva; Heather Francis; Gianluca Svegliati Baroni; Antonio Benedetti; David Brenner; Domenico Alvaro; Gianfranco Alpini; Marco Marzioni
Journal:  Dig Liver Dis       Date:  2012-11-22       Impact factor: 4.088

6.  Effects of aspirin and enoxaparin in a rat model of liver fibrosis.

Authors:  Chen-Jie Li; Zhi-Hui Yang; Xiao-Liu Shi; De-Liang Liu
Journal:  World J Gastroenterol       Date:  2017-09-21       Impact factor: 5.742

7.  'Hardcore' OX40+ immunosuppressive regulatory T cells in hepatic cirrhosis and cancer.

Authors:  Silvia Piconese; Eleonora Timperi; Vincenzo Barnaba
Journal:  Oncoimmunology       Date:  2014-06-17       Impact factor: 8.110

Review 8.  Regulatory T-cells promote hepatitis B virus infection and hepatocellular carcinoma progression.

Authors:  Wei Li; Jun Han; Hong Wu
Journal:  Chronic Dis Transl Med       Date:  2016-11-09

9.  Chronic liver injury promotes hepatocarcinoma cell seeding and growth, associated with infiltration by macrophages.

Authors:  Bénédicte Delire; Patrick Henriet; Pascale Lemoine; Isabelle A Leclercq; Peter Stärkel
Journal:  Cancer Sci       Date:  2018-06-09       Impact factor: 6.716

10.  Hyperglycemia aggravates acute liver injury by promoting liver-resident macrophage NLRP3 inflammasome activation via the inhibition of AMPK/mTOR-mediated autophagy induction.

Authors:  Qi Wang; Song Wei; Shun Zhou; Jiannan Qiu; Chenyu Shi; Rui Liu; Haoming Zhou; Ling Lu
Journal:  Immunol Cell Biol       Date:  2019-11-19       Impact factor: 5.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.